Tuesday, 24 September 2019

Metformin use in PCO--its rationality


Point 12: What do a PCO woman is benefitted by decrease of serum FSH? How it helps at granulosa cell level?? Ans: The indirect   role of metformin on granulosa cells by decreseing IGF-1 . This is very impotrtnat and most important opath, at least I feel in that way that IGF-1 is notorious to cause & propagate PCO. Metformin , at the ovarian   level with its    hyperandrogenic intra follicular    pattern  cause improved function  by a   decrease   in IGF-1   availability  that has an important  role in  controlling  granulosa   cell aromatase   levels.

Point 13: PCOS have higher   levels of FSH  receptor    expression  compared with those   from normal   ovaries .Ans:-
It has been shown that granulosa cells from women with metformin reduces  FSH      without     altering   cAMP  levels.  This involves blocking activation    of CRE  on promoter  ii of CYP19   via inhibition of pCREB   and possible    disruption  of the formation of the CREB – CRTC  2  co activator complex.  This is   via an  AMPK  independent    mechanism . 
Metformin   is available as 500, 850 and 1,000 mg  tablets with a target   dose of  1,500-2,550 mg / day Dosage  and side  effects
.
Metformin  has a dose dependent    absorption  in humans   and its   bioavailability  is  limited to 50-60 %   because   the amount    available   may result    from pre  systemic    clearance  or binding to the intestinal wall.
Therapeutic regimens of metformin    administration are not well  standardized   and its dose   should probably be adjusted  according   to the patient’s   BMI   and insulin  resistance .
For example it was  demonstrated   that nonobese  women with PCOS  respond better than obese women to metformin    treatment   at a dosage  of 1,500   mg/ day   for 6 months   Nonobese    women in fact  showed a statistically   significant    decrease   in serum androgen    level   and fasting insulin level and also an  improvement  in menstrual  cyclicity    . Moreover   it is    possible   that women    who did not respond   to metformin   1.5 g dose  per day   might show  clinical   changes   if the dose is increased  to 2 g.

Common   side effects are gastrointestinal   such as   diarrhea nausea vomiting   bloating  abdominal  discomfort flatulence and  unpleasant metallic taste   in the mouth.
Lactic   acidosis   and hypoglycemia are very rare.
To reduce  these side  effects. It is recommended to start  metformin  with a low   dose  and then   gradually  increase  within a period  of  4-6 weeks.
Metformin  may cause vitamin  B12  malabsorption  and so  every   patient   should be  monitored for signs   and symptoms  of vitamin  B 12     deficiency    numbness paresthesia  macroglossia  behavioral     changes   and pernicious anemia.
Metformin   prescription      should be avoided  in women   with renal   insufficiency   congestive  heart     failure    sepsis   or hepatic   dysfunction
Therefore   testing  of hepatic  and renal    function is  necessary  in advance   of prescription  and thereafter yearly   testing  is indicated.
However   it has been   demonstrated    that metformin use for up to 6 months  dose not adversely affect renal   or liver   function    in  a large   sample  of  PCOS   women even   those with   mildly  abnormal    baseline    hepatic  parameters

No comments:

Post a Comment